Konakion Mm Paediatric (Phytomenadione)

Phytomenadione serves as a cofactor for the enzyme gamma‑glutamyl carboxylase, which adds a carboxyl group to specific glutamate residues on clotting factors II, VII, IX, and X. This modification enables the factors to bind calcium and become biologically active, restoring normal blood coagulation.

The dose of Konakion Mm Paediatric is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and route of administration. Healthcare professionals follow established guidelines and adjust the amount as needed for each individual case.

Safety data for phytomenadione in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Konakion Mm Paediatric contains phytomenadione, the same active form of vitamin K1 found in most vitamin K preparations. Compared with synthetic analogues, phytomenadione has a well‑established safety profile and is widely used for neonatal prophylaxis and anticoagulant reversal, offering reliable bioavailability across multiple routes.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and avoid exposure to extreme temperatures. Follow any additional handling instructions provided by the manufacturer.

Konakion Mm Paediatric can be given by intramuscular injection, intravenous infusion, or oral administration, depending on the clinical situation and the prescriber's judgment. The route is selected to achieve the desired therapeutic effect while considering patient age and condition.

Serious risks include severe allergic reactions such as anaphylaxis, hemolysis, thrombosis, and paradoxical bleeding despite therapy. Patients should be monitored for signs of hypersensitivity, sudden drop in blood pressure, or unexpected bleeding, and medical attention should be sought immediately if these occur.

Konakion Mm Paediatric should be avoided in individuals with a known hypersensitivity to phytomenadione or any of the product’s excipients. It should also be used with caution in patients with severe liver disease or those receiving medications that may interact significantly, as directed by a healthcare professional.